Metrics Contract to assist ESSA on oral oncology drug development

“We are excited to partner with ESSA on a program that is ultimately intended to benefit cancer patients. Our focus is keenly on novel drugs that make a difference”

Metrics Contract Services, the US-based CDMO division of Mayne Pharma, has announced the signing of a development and manufacturing agreement with ESSA Pharmaceuticals. Under the agreement, Metrics will provide formulation development, analytical services and manufacturing to support the client’s development of an orally administered oncology drug.

“To support this project for ESSA Pharmaceuticals, Metrics will transfer their current tablet formulation and manufacturing process into our facility, perform development work to optimize the formulation, then scale up the process to be able to manufacture clinical supplies for ESSA’s clinical needs,” said John Ross, President of Metrics Contract Services.

The project will enable Metrics to demonstrate its expertise in supporting customers with development programs and its ability to support commercial production from the same campus, the CDMO says.

“We are excited to partner with ESSA on a program that is ultimately intended to benefit cancer patients. Our focus is keenly on novel drugs that make a difference.”

Companies